Core Viewpoint - Yiming Oncology has terminated its licensing agreement with Axion Bio, Inc., regaining global development and commercialization rights for two core anti-cancer drugs, IMM2510 and IMM27M, while retaining the previously received $35 million upfront and milestone payments [1] Group 1 - Yiming Oncology announced the termination of the licensing agreement with Axion Bio, Inc. [1] - The agreement was initially established on August 1, 2024, granting Axion exclusive rights for the development and commercialization of IMM2510 and IMM27M outside Greater China [1] - Following the termination, all global rights for the drugs revert to Yiming Oncology, with Axion receiving limited rights to gradually conclude its related clinical development activities [1]
宜明昂科：终止与美国Axion Bio,Inc.的授权合作协议，已收3500万美元款项不受影响